Exosome-Based Therapeutics for Targeted Cancer Treatment
Exousia Pro, Inc. (EXO), a leader in exosome-based biotechnology, develops and manufactures mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. EXO’s breakthrough platform enables the custom production of exosomes with enhanced genetic functionality, capable of selectively targeting specific cells to address diseases with significant unmet medical needs. These engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer, thereby improving patient responsiveness to anticancer therapies. The same platform technology also holds promise for treating a broad spectrum of viral infections.
What are Exosomes
Exosomes are small, membrane-bound vesicles that are released by cells into the extracellular environment. They are typically 30-100 nanometers in diameter and contain various proteins, lipids, DNA, and RNA.
Function:
Exosomes play a crucial role in intercellular communication and transport. They carry bioactive molecules, such as growth factors, cytokines, and miRNAs, to other cells, where they can influence cellular processes, including: Cell proliferation, Differentiation, Immune regulation, and Tissue repair.
Origin:
Exosomes are produced by a process called multivesicular body (MVB) biogenesis. In this process, intracellular vesicles bud from the endoplasmic reticulum and fuse with each other, forming MVBs. The MVBs then migrate to the cell membrane and release their vesicles, known as exosomes, into the extracellular space.
Applications:
Exosomes have gained significant attention in various fields, including:
- Medicine:
Exosomes from stem cells have been investigated as potential treatments for skin regeneration, wound healing, and cancer. - Cosmetics:
Exosomes from platelets and other sources are used in skincare products to promote anti-aging and skin rejuvenation. - Drug delivery:
Exosomes can be engineered to carry therapeutic drugs and deliver them to specific cells or tissues. - Biomarkers:
Exosomes contain molecular markers that can reflect the health status of the cells that produced them, making them potential biomarkers for disease diagnosis.
- Medicine:
Exosome-Based Therapeutics for Targeted Cancer Treatment
Exousia Pro, Inc. (EXO), a leader in exosome-based biotechnology, develops and manufactures mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. EXO’s breakthrough platform enables the custom production of exosomes with enhanced genetic functionality, capable of selectively targeting specific cells to address diseases with significant unmet medical needs. These engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer, thereby improving patient responsiveness to anticancer therapies. The same platform technology also holds promise for treating a broad spectrum of viral infections.
What are Exosomes
Exosomes are small, membrane-bound vesicles that are released by cells into the extracellular environment. They are typically 30-100 nanometers in diameter and contain various proteins, lipids, DNA, and RNA.
Function:
Exosomes play a crucial role in intercellular communication and transport. They carry bioactive molecules, such as growth factors, cytokines, and miRNAs, to other cells, where they can influence cellular processes, including: Cell proliferation, Differentiation, Immune regulation, and Tissue repair.
Origin:
Exosomes are produced by a process called multivesicular body (MVB) biogenesis. In this process, intracellular vesicles bud from the endoplasmic reticulum and fuse with each other, forming MVBs. The MVBs then migrate to the cell membrane and release their vesicles, known as exosomes, into the extracellular space.
Applications:
Exosomes have gained significant attention in various fields, including:
- Medicine:
Exosomes from stem cells have been investigated as potential treatments for skin regeneration, wound healing, and cancer. - Cosmetics:
Exosomes from platelets and other sources are used in skincare products to promote anti-aging and skin rejuvenation. - Drug delivery:
Exosomes can be engineered to carry therapeutic drugs and deliver them to specific cells or tissues. - Biomarkers:
Exosomes contain molecular markers that can reflect the health status of the cells that produced them, making them potential biomarkers for disease diagnosis.
- Medicine:
Lead Program: Glioblastoma (GBM)
Glioblastoma is the most common malignant brain tumor in adults, typically affecting older adults with a median age of 64 at diagnosis. It is relatively rare overall, with an estimated annual incidence of about 3 to 5 cases per 100,000 people in developed countries.
Frequency in adults
- More common in older adults: The risk of glioblastoma increases with age, peaking in people between 65 and 75 years old.
- Higher incidence in men: Men are diagnosed with glioblastoma about 1.5 times more often than women.
- Most common malignant brain tumor: Despite its rarity in the general population, glioblastoma accounts for approximately 45–50% of all primary malignant brain cancers in adults.
- Approximately 12,000 to 15,000 people are diagnosed with glioblastoma per year in the U.S. This figure represents the annual number of new cases for this aggressive type of primary brain cancer.
Corporate approach to treating rare, devastating cancers.
- Obtain Orphan Drug Designation for our proprietary therapy.
- Hundreds of different types of cancer have received orphan drug designation (ODD) from regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This status is granted to encourage the development of treatments for rare diseases, which affect fewer than 200,000 people in the U.S. Common examples of cancers with numerous orphan applications include:
- Acute myelocytic leukemia (AML): A rare blood cancer that had 131 orphan designations at one point.
- Pancreatic cancer: A difficult-to-treat cancer with more than 100 orphan designations.
- Glioblastoma multiforme (GBM): An aggressive type of brain tumor.
- Multiple myeloma: A type of blood cancer affecting plasma cells.
- Gastric (stomach) cancer.
- Neuroblastoma: A rare childhood cancer that develops from immature nerve cells.
- Myelodysplastic syndrome (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells.
- Receiving orphan drug designation provides incentives to drug developers, such as protocol assistance, fee reductions, and market exclusivity, which helps encourage the development of new therapies for the disease.
Beyond Glioblastoma:
Our exosome platform extends to:
- Neurodegenerative diseases (Alzheimer’s, Parkinson’s)
- Other cancers (pancreatic, breast, lung, ovarian, liver)
- Dermatology & regenerative medicine (commercial revenue today)
- Diagnostics (liquid biopsy development)
Investment Highlights:
Market
$304.5M exosome market growing at 28.7% CAGR
IP
Patented one-step manufacturing process
Clinical Data
Statistically significant tumor suppression in preclinical GBM models
Pipeline
Multiple revenue streams - clinical oncology programs + commercial dermatology products
Team
Led by biotech veteran Mike Sheikh (took drug from concept to Phase 1 in 10 months)
Status
$5.0M market cap, uplisting to major exchange in progress
Ready to Learn More?
For Investors:
Download our investor presentation or view our OTC Markets profile
